Item 8.01. Other Events.

On January 25, 2023, INmune Bio Inc. (the "Company") issued a press release announcing pre-clinical data that supports an approach to treating Duchenne Muscular Dystrophy to decrease muscle damage and significantly increase muscle regeneration. A copy of this press release is attached herewith as Exhibit 99.1.

Item 9.01 Financial statements and Exhibits





(d) Exhibits.



99.1      Press Release dated January 25, 2023
104     Cover Page Interactive Data File (embedded within the Inline XBRL document)




                                       1

© Edgar Online, source Glimpses